Restasis for the treatment of 'dry eye' in Aotus nancymaae.
BACKGROUND
This case report describes the treatment of three male owl monkeys (Aotus nancymaae) diagnosed with chronic dry eye with a topical cyclosporine product, Restasis, approved for use in humans. These owl monkeys had ocular disease resulting from procedures performed at a biotechnology company. They were moved to the Center for Neotropical Primate Research and Resources at University of South Alabama to be incorporated into the breeding colony.


METHODS
Schirmer tear testing was performed initially and during the course of treatment to monitor efficacy of twice daily administered Restasis. The goals of treatment were to reduce pain and/or distress and if possible to quantitatively increase tear production.


CONCLUSIONS
All animals had improvements in conjunctival inflammation and had an increase in tear production.
Schuler
A M
AM
Department of Comparative Medicine, University of South Alabama, AL, USA. mschuler@usouthal.edu
Tustin
G T
GT
Abee
C R
CR
Scammell
J G
JG
D000818:Animals; D016645:Aotidae; D016572:Cyclosporine / Q000627:therapeutic use*; D015352:Dry Eye Syndromes / Q000188:drug therapy / Q000662:veterinary*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008992:Monkey Diseases / Q000188:drug therapy*; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D016572:Cyclosporine